<DOC>
	<DOC>NCT00046488</DOC>
	<brief_summary>To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.</brief_summary>
	<brief_title>Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Signed IRBapproved informed consent. Greater than 18 years of age Proof of CD23+ CLL or small lymphocytic lymphoma (SLL) Progressive disease after at least 1 course of chemotherapy Acceptable hematologic status, liver function, renal function, and pulmonary function Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment Previous exposure to IDEC152 or other antiCD23 antibodies Presence of HIV infection or AIDS Serious nonmalignant disease Active uncontrolled bacterial, viral or fungal infections. Clinically active autoimmune disease Pregnant or currently breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Chronic Lymphoblastic Leukemia</keyword>
	<keyword>Leukemia, Lymphoblastic, Chronic</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>